X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (391) 391
Publication (34) 34
Book Chapter (6) 6
Conference Proceeding (4) 4
Book Review (1) 1
Dissertation (1) 1
Patent (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (150) 150
hematology (115) 115
index medicus (97) 97
female (77) 77
male (77) 77
middle aged (72) 72
aged (65) 65
adult (64) 64
leukemia, lymphocytic, chronic, b-cell - drug therapy (54) 54
treatment outcome (42) 42
antibodies, monoclonal - therapeutic use (41) 41
oncology (39) 39
antibodies, monoclonal, humanized (36) 36
aged, 80 and over (35) 35
rituximab (34) 34
fludarabine (33) 33
survival (32) 32
cll (30) 30
leukemia (30) 30
chronic lymphocytic leukaemia (29) 29
flow cytometry (28) 28
alemtuzumab (27) 27
abridged index medicus (26) 26
antineoplastic agents - therapeutic use (26) 26
chronic lymphatic leukemia (26) 26
diagnosis (26) 26
therapy (26) 26
chronic lymphocytic-leukemia (24) 24
leukemia, lymphocytic, chronic, b-cell - mortality (24) 24
leukemia, lymphocytic, chronic, b-cell - pathology (24) 24
antineoplastic combined chemotherapy protocols - therapeutic use (23) 23
disease-free survival (23) 23
leukemia, lymphocytic, chronic, b-cell - diagnosis (23) 23
hemoglobinuria, paroxysmal - blood (22) 22
leukemia, lymphocytic, chronic, b-cell - genetics (21) 21
prognosis (21) 21
antibodies, monoclonal - adverse effects (20) 20
cancer (20) 20
chronic lymphocytic leukemia (20) 20
clinical trials (20) 20
cyclophosphamide (20) 20
antibodies, monoclonal - administration & dosage (19) 19
care and treatment (19) 19
hemoglobinuria, paroxysmal - drug therapy (19) 19
minimal residual disease (19) 19
mutation (19) 19
chemotherapy (18) 18
leukemia, lymphocytic, chronic, b-cell - therapy (18) 18
natural-history (18) 18
patients (18) 18
vidarabine - analogs & derivatives (17) 17
follow-up studies (16) 16
hemolysis (16) 16
medicine, general & internal (16) 16
hematology, oncology and palliative medicine (15) 15
hemic and lymphatic diseases (15) 15
hemoglobinuria, paroxysmal - therapy (15) 15
lymphoma (15) 15
medical research (15) 15
pig-a gene (15) 15
recurrence (15) 15
adolescent (14) 14
disease (14) 14
ibrutinib (14) 14
open-label (14) 14
antibodies, neoplasm - therapeutic use (13) 13
antineoplastic combined chemotherapy protocols - adverse effects (13) 13
hemoglobinuria, paroxysmal - diagnosis (13) 13
pyrazoles - therapeutic use (13) 13
pyrimidines - therapeutic use (13) 13
young adult (13) 13
deficiency (12) 12
eculizumab (12) 12
guidelines (12) 12
hemoglobinuria, paroxysmal - complications (12) 12
hemolysis - drug effects (12) 12
analysis (11) 11
antineoplastic agents - administration & dosage (11) 11
antineoplastic agents - adverse effects (11) 11
b-lymphocytes - immunology (11) 11
complement inhibitor eculizumab (11) 11
drug therapy (11) 11
expression (11) 11
immunophenotyping (11) 11
management (11) 11
remission induction (11) 11
research (11) 11
stem-cell transplantation (11) 11
survival rate (11) 11
antibodies, monoclonal - pharmacology (10) 10
blood transfusion (10) 10
disease progression (10) 10
inhibitor (10) 10
neoplasm staging (10) 10
paroxysmal nocturnal haemoglobinuria (10) 10
pnh (10) 10
pyrazoles - adverse effects (10) 10
pyrimidines - adverse effects (10) 10
antibody (9) 9
glycosylphosphatidylinositols - deficiency (9) 9
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9980, pp. 1873 - 1883
Summary Background Treatment for patients with chronic lymphocytic leukaemia who are elderly or who have comorbidities is challenging because fludarabine-based... 
Internal Medicine | BENDAMUSTINE | 1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | CLL | CYCLOPHOSPHAMIDE | CHEMOIMMUNOTHERAPY | RITUXIMAB | MONOCLONAL-ANTIBODIES | ELDERLY-PATIENTS | FLUDARABINE | HUMAN CD20 | Age Distribution | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Chlorambucil - adverse effects | Prospective Studies | Chlorambucil - therapeutic use | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents, Alkylating - administration & dosage | Aged, 80 and over | Adult | Female | Chlorambucil - administration & dosage | Drug Administration Schedule | Kaplan-Meier Estimate | Treatment Outcome | Antineoplastic Agents, Alkylating - therapeutic use | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Sex Distribution | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Antineoplastic Agents, Alkylating - adverse effects | Chlorambucil | Medical colleges | Hospitals | Comorbidity | United Kingdom | Product development | India | Medical research | Flow cytometry | Immunoglobulins | Medical imaging | Laboratories | Cytotoxicity | Infections | Ovarian cancer | Bone marrow | Drug dosages | Age | Binding sites | Geriatrics | Neutropenia
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 3, pp. 297 - 311
Journal Article
Nature Genetics, ISSN 1061-4036, 10/2008, Volume 40, Issue 10, pp. 1204 - 1210
Journal Article
Blood, ISSN 0006-4971, 06/2013, Volume 121, Issue 25, pp. 4985 - 5105
The most frequent and feared complication of paroxysmal nocturnal hemoglobinuria (PNH) is thrombosis. Recent research has demonstrated that the complement and... 
PLASMINOGEN-ACTIVATOR | COMPLEMENT INHIBITOR ECULIZUMAB | NITRIC-OXIDE | DEEP-VEIN THROMBOSIS | BUDD-CHIARI-SYNDROME | HEPARIN-INDUCED THROMBOCYTOPENIA | RED-BLOOD-CELLS | SICKLE-CELL-DISEASE | NATURAL-HISTORY | HEMATOLOGY | FACTOR PATHWAY INHIBITOR | Thrombosis - etiology | Hemoglobinuria, Paroxysmal - complications
Journal Article
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, ISSN 1520-4391, 2011, Volume 2011, pp. 104 - 109
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2014, Volume 370, Issue 11, pp. 997 - 1007
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2016, Volume 374, Issue 4, pp. 323 - 332
Acalabrutinib is an irreversible inhibitor of Bruton's tyrosine kinase with greater specificity for the enzyme than the first-in-class agent, ibrutinib. It had... 
B-CELL RECEPTOR | MEDICINE, GENERAL & INTERNAL | ACTIVATION | IN-VIVO | X-LINKED AGAMMAGLOBULINEMIA | IBRUTINIB | BTK | PCI-32765 | TYROSINE KINASE INHIBITOR | LYMPHOMA | OPEN-LABEL | Recurrence | Benzamides - pharmacokinetics | Humans | Middle Aged | Pyrazines - administration & dosage | Male | Antineoplastic Agents - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Protein Kinase Inhibitors - adverse effects | Diarrhea - chemically induced | Dose-Response Relationship, Drug | Benzamides - administration & dosage | Antineoplastic Agents - adverse effects | Female | Antineoplastic Agents - pharmacokinetics | Benzamides - adverse effects | Headache - chemically induced | Chromosome Deletion | Protein Kinase Inhibitors - pharmacokinetics | Administration, Oral | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Agammaglobulinaemia Tyrosine Kinase | Pyrazines - pharmacokinetics | Pyrazines - adverse effects | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Treatment outcome | Usage | Care and treatment | Safety and security measures | Lymphocytic leukemia | Analysis | Clinical trials | Pharmacology | Dosage and administration | Pharmacokinetics | Antineoplastic agents | Tyrosine | Headache | Pharmacodynamics | Transformation | Chronic lymphatic leukemia | Inhibitor drugs | Leukemia | Diarrhea | Chromosome deletion | Lymphatic leukemia | Kinases | Lymphoma | Bruton's tyrosine kinase | Patients | Clonal deletion | Lymphomas | Safety | Drug therapy | Lymphocytosis | Protein-tyrosine kinase | Chromosome 17 | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2015, Volume 373, Issue 25, pp. 2425 - 2437
Journal Article